This will take effect May 13, 2013
Overview and Clinical Utility:
PathGroup is now performing HPV Genotyping using the APTIMA HPV 16 18/45 assay by GenProbe. Genotyping will be performed upon client request based on an “HPV Positive – HIGH Risk” result. PathGroup’s HPV Genotyping is a qualitative assay for the three most common HPV genotypes (16, 18 and 45) – associated with approximately 80% of all invasive cervical cancers. This assay allows for rapid risk stratification and is ASCCP recommended for patients who are HPV positive high risk via DNA testing.
Click Here to read more.